ArticleJournal of the American Chemical Society2025
Small Molecule Catalyst for Peptide Synthesis.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmaceutical Peptides: From Synthesis and Mechanistic Pharmacology to Future Biologic Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- OBIMAP (One-Bead Interchain Multipeptide Assembly Platform).ACS bio & med chem Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide synthesis is a highly optimized process that has led to the production of new classes of therapeutics and materials. The process of peptide synthesis is straightforward: commercially available, orthogonally protected amino acids can be linked on the solid phase using highly efficient coupling agents. However, the simplicity of peptide synthesis masks a significant drawback of the current method: it is highly wasteful and utilizes a solvent that is facing restrictions on its use. A catalyst that allows solid phase synthesis of peptides in benign solvents without requirement for excess reagents and protected amino acids would have a significant impact. Here, we describe the development of a small molecule catalyst for peptide synthesis. The catalyst design incorporates redox recycling of diselenide and phosphine with air as the ultimate oxidant and phenylsilane as the ultimate reductant. The catalyst affords efficient coupling of amino acids in the solution and solid phase. Significantly, the catalyst functions with acetonitrile, bypassing the need for DMF. The current effort builds on mechanistic analysis of reaction rates and intermediates in our prior work which led to a hydrogen bonding catalyst: [Handoko; ; Panigrahi, N. R.; Arora, P. S.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.